HomeAbout usHospitalsSearchLogin
Your medical data, safe and secure.
Name
CMLVAX100
Description
CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
No brand information found.
